{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:48:26Z","timestamp":1791848906922,"version":"4.3.4"},"reference-count":171,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.autrev.2012.06.004","type":"journal-article","created":{"date-parts":[[2012,6,26]],"date-time":"2012-06-26T20:32:06Z","timestamp":1340742726000},"page":"363-373","source":"Crossref","is-referenced-by-count":159,"title":["Overlap connective tissue disease syndromes"],"prefix":"10.1016","volume":"12","author":[{"given":"Luca","family":"Iaccarino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariele","family":"Gatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvano","family":"Bettio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Caso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariaelisa","family":"Rampudda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Zen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ghirardello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Punzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Doria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2012.06.004_bb0005","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.06.004_bb0010","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.06.004_bb0015","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sj\u00f6gren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.06.004_bb0020","first-page":"1","article-title":"Preliminary criteria for the classification of systemic sclerosis (scleroderma)","volume":"31","author":"Masi","year":"1981","journal-title":"Bull Rheum Dis"},{"key":"10.1016\/j.autrev.2012.06.004_bb0025","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2012.06.004_bb0030","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2012.06.004_bb0035","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.autrev.2011.04.007","article-title":"Anti-annexins autoantibodies: their role as biomarkers of autoimmune diseases","volume":"10","author":"Iaccarino","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.06.004_bb0040","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.autrev.2010.09.013","article-title":"Undifferentiated connective tissue diseases (UCTD): simplified systemic autoimmune diseases","volume":"10","author":"Mosca","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.06.004_bb0045","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.autrev.2011.10.021","article-title":"Autoantibodies in lupus: culprits or passive bystanders?","volume":"11","author":"Rekvig","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.06.004_bb0050","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.autrev.2011.10.020","article-title":"Systemic lupus erythematosus one disease or many?","volume":"11","author":"Agmon-Levin","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.06.004_bb0055","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.autrev.2011.10.023","article-title":"Controversies in rheumatism and autoimmunity","volume":"11","author":"Doria","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.06.004_bb0060","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.berh.2012.01.009","article-title":"Mixed connective tissue disease: an overview of clinical manifestations, diagnosis and treatment","volume":"26","author":"Ortega-Hernandez","year":"2012","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0065","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.semarthrit.2011.07.010","article-title":"\u201cTo be or not to be,\u201d ten years after: evidence for mixed connective tissue disease as a distinct entity","volume":"41","author":"Cappelli","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.06.004_bb0070","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nrneurol.2011.63","article-title":"Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis","volume":"7","author":"Mammen","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0075","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s12016-010-8238-7","article-title":"Cutting edge issues in polymyositis","volume":"41","author":"Ghirardello","year":"2011","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0080","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jbspin.2009.08.008","article-title":"Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: relevance for clinical classification: retrospective study of 169 patients","volume":"77","author":"V\u00e1ncsa","year":"2010","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.autrev.2012.06.004_bb0085","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/08916930600622132","article-title":"Update on idiopathic inflammatory myopathies","volume":"39","author":"Briani","year":"2006","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2012.06.004_bb0090","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1378\/chest.08-2233","article-title":"Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature","volume":"135","author":"Kalluri","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2012.06.004_bb0095","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/08916930400022640","article-title":"Anti-Jo-1 antibodies","volume":"38","author":"Zampieri","year":"2005","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2012.06.004_bb0100","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.autrev.2011.09.007","article-title":"Interstitial lung disease outcomes by high-resolution computed tomography (HRCT) in anti-Jo1 antibody-positive polymyositis patients: a single centre study and review of the literature","volume":"11","author":"Ingegnoli","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.06.004_bb0105","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/08916930600623791","article-title":"In patients with antisynthetase syndrome the occurrence of anti-Ro\/SSA antibodies causes a more severe interstitial lung disease","volume":"39","author":"La Corte","year":"2006","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2012.06.004_bb0110","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.06.004_bb0115","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1445-5994.2010.02164.x","article-title":"Clinical heterogeneity and prognostic features of South Australian patients with anti-synthetase autoantibodies","volume":"41","author":"Dugar","year":"2011","journal-title":"Intern Med J"},{"key":"10.1016\/j.autrev.2012.06.004_bb0120","article-title":"Anticyclic citrullinated peptide antibodies as markers of erosive arthritis in antisynthetase syndrome","volume":"37","author":"Cavagna","year":"1967","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0125","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/RHU.0b013e3181b0e910","article-title":"Clinical characteristics of patients with anti-Jo-1 antibodies: a single centre experience","volume":"15","author":"Mileti","year":"2009","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0130","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/08916930600623767","article-title":"Clinical features and prognosis of patients with idiopathic inflammatory myopathies and anti-Jo-1 antibodies","volume":"39","author":"Mielnik","year":"2006","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2012.06.004_bb0135","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1136\/thx.2006.069237","article-title":"Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset","volume":"63","author":"Tillie-Leblond","year":"2008","journal-title":"Thorax"},{"key":"10.1016\/j.autrev.2012.06.004_bb0140","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.autrev.2006.11.001","article-title":"Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic diseases?","volume":"6","author":"Iaccarino","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.06.004_bb0145","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.autrev.2011.04.026","article-title":"Refractory disease in autoimmune diseases","volume":"10","author":"Vasconcelos","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.06.004_bb0150","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/rheumatology\/kep157","article-title":"Rituximab treatment of the anti-synthetase syndrome: a retrospective case series","volume":"48","author":"Sem","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2012.06.004_bb0155","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.3899\/jrheum.101248","article-title":"Clinical and serological hallmarks of systemic sclerosis overlap syndromes","volume":"38","author":"Pakozdi","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0160","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00296-006-0207-3","article-title":"Coexistence of systemic sclerosis with other autoimmune diseases","volume":"27","author":"Caramaschi","year":"2007","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2012.06.004_bb0165","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/rheumatology\/ken179","article-title":"The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement","volume":"47","author":"Hunzelmann","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2012.06.004_bb0170","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jaut.2008.05.002","article-title":"Polyautoimmunity and familial autoimmunity in systemic sclerosis","volume":"31","author":"Hudson","year":"2008","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2012.06.004_bb0175","first-page":"14","article-title":"Scleroderma overlap syndrome","volume":"13","author":"Balbir-Gurman","year":"2011","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.autrev.2012.06.004_bb0180","article-title":"Anti-PM\u2013Scl antibody in patients with systemic sclerosis","author":"Koschik","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0185","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01.md.0000173991.74008.b0","article-title":"Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients","volume":"84","author":"Troyanov","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2012.06.004_bb0190","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1136\/jcp.54.5.340","article-title":"Autoantibodies and overlap syndromes in autoimmune rheumatic disease","volume":"54","author":"Jury","year":"2001","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0195","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1468-3083.2004.00869.x","article-title":"Scleromyositis (scleroderma\/polymyositis overlap) is an entity","volume":"18","author":"Jablonska","year":"2004","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0200","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00005792-199211000-00001","article-title":"The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM\u2013Scl","volume":"71","author":"Marguerie","year":"1992","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2012.06.004_bb0205","first-page":"129","article-title":"Anti-PM\/Scl antibodies in connective tissue disease: clinical and biological assessment of 14 patients","volume":"24","author":"Vandergheynst","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0210","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/BF00915286","article-title":"Antibodies to a nuclear\/nucleolar antigen in patients with polymyositis overlap syndromes","volume":"4","author":"Reichlin","year":"1984","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0215","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/art.1780330508","article-title":"Immunogenetic associations of scleroderma-related antinuclear antibodies","volume":"33","author":"Genth","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.06.004_bb0220","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/art.1780351014","article-title":"Serum autoantibody to the nucleolar antigen PM\u2013Scl. Clinical and immunogenetic associations","volume":"35","author":"Oddis","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.06.004_bb0225","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.autrev.2010.05.020","article-title":"Anti-Ku antibodies: clinical, genetic and diagnostic insights","volume":"9","author":"Belizna","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.06.004_bb0230","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/0961203308089442","article-title":"Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune diseases","volume":"17","author":"Cavazzana","year":"2008","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2012.06.004_bb0235","first-page":"1393","article-title":"Anti-Ku antibodies in connective tissue diseases: clinical and serological evaluation of 14 patients","volume":"29","author":"Franceschini","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0240","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/08916930400022681","article-title":"Anti-Mi-2 antibodies","volume":"38","author":"Ghirardello","year":"2005","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2012.06.004_bb0245","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/08916930400022640","article-title":"Anti-Jo-1 antibodies","volume":"38","author":"Zampieri","year":"2005","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2012.06.004_bb0250","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1136\/ard.2005.040717","article-title":"Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen","volume":"65","author":"Hengstman","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.06.004_bb0255","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/08916930500050145","article-title":"Overlap syndromes in the context of shared autoimmunity","volume":"38","author":"Rodr\u00edguez-Reyna","year":"2005","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2012.06.004_bb0260","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/BF01451281","article-title":"Scleromyositis: a scleroderma\/polymyositis overlap syndrome","volume":"17","author":"Jablonska","year":"1998","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0265","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.autrev.2009.12.005","article-title":"Polymyositis, dermatomyositis and malignancy: a further intriguing link","volume":"9","author":"Zampieri","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.06.004_bb0270","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.autrev.2011.05.013","article-title":"Pathogenesis and therapies of immune-mediated myopathies","volume":"11","author":"Dalakas","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.06.004_bb0275","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1002\/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O","article-title":"Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis","volume":"41","author":"Steen","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.06.004_bb0280","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/art.20195","article-title":"Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study","volume":"50","author":"Levy","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.06.004_bb0285","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/BOR.0b013e32834aa40b","article-title":"Contemporary management of Raynaud's phenomenon and digital ischemic complications","volume":"23","author":"Herrick","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0290","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","article-title":"Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases","volume":"86","author":"Ramos-Casals","year":"2007","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2012.06.004_bb0295","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/art.20849","article-title":"Rituximab in the treatment of dermatomyositis: an open-label pilot study","volume":"52","author":"Levine","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.06.004_bb0300","first-page":"1864","article-title":"Rituximab for refractory polymyositis: an open-label prospective study","volume":"34","author":"Mok","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0305","first-page":"374","article-title":"Sj\u00f6gren's syndrome in SLE: part I. The frequency of the clinical and subclinical features of Sj\u00f6gren's syndrome in patients with SLE","volume":"86","author":"Grennan","year":"1977","journal-title":"N Z Med J"},{"key":"10.1016\/j.autrev.2012.06.004_bb0310","first-page":"201","article-title":"Sj\u00f6gren's syndrome in systemic lupus erythematosus","volume":"17","author":"Andonopoulos","year":"1990","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0315","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1191\/096120398678920046","article-title":"Systemic lupus erythematosus VII: frequency and impact of secondary Sj\u00f6gren's syndrome","volume":"7","author":"Nossent","year":"1998","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2012.06.004_bb0320","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1136\/ard.59.3.230","article-title":"Development of additional autoimmune diseases in a population of patients with systemic lupus erythematosus","volume":"59","author":"McDonagh","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.06.004_bb0325","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/ard.60.12.1103","article-title":"Sicca symptoms and secondary Sj\u00f6gren's syndrome in systemic lupus erythematosus: comparison with rheumatoid arthritis and correlation with disease variables","volume":"60","author":"Gilboe","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.06.004_bb0330","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/art.20093","article-title":"Sj\u00f6gren's syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sj\u00f6gren's syndrome","volume":"50","author":"Manoussakis","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.06.004_bb0335","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3899\/jrheum.090804","article-title":"Secondary Sj\u00f6gren's syndrome in systemic lupus erythematosus defines a distinct disease subset","volume":"37","author":"Baer","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0340","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jaut.2003.12.005","article-title":"Antinucleosome antibodies in SLE: a two-year follow-up study of 101 patients","volume":"22","author":"Ghirardello","year":"2004","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2012.06.004_bb0345","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.semarthrit.2006.08.007","article-title":"The overlap of Sj\u00f6gren's syndrome with other systemic autoimmune diseases","volume":"36","author":"Ramos-Casals","year":"2007","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.06.004_bb0350","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1177\/0961203309353172","article-title":"Systemic lupus erythematosus and Sj\u00f6gren's syndrome induced in a case by interferon-alpha used for the treatment of hepatitis C","volume":"19","author":"Onishi","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2012.06.004_bb0355","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1177\/0961203310374305","article-title":"Epidemiology of systemic lupus erythematosus in Asia","volume":"19","author":"Osio-Salido","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2012.06.004_bb0360","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sj\u00f6gren's syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.06.004_bb0365","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MD.0b013e318190f170","article-title":"A systematic review of the off-label use of biological therapies in systemic autoimmune diseases","volume":"87","author":"Ramos-Casals","year":"2008","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2012.06.004_bb0370","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.autrev.2007.11.004","article-title":"Preventive strategies in systemic lupus erythematosus","volume":"7","author":"Doria","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.06.004_bb0375","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/0961203311402246","article-title":"Glucocorticoid-induced diabetes mellitus in patients with systemic lupus erythematosus treated with high-dose glucocorticoid therapy","volume":"20","author":"Ha","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2012.06.004_bb0380","first-page":"354","article-title":"High incidence rate of vertebral fractures during chronic prednisone treatment, in spite of bisphosphonate or alfacalcidol use. Extension of the alendronate or alfacalcidol in glucocorticoid-induced osteoporosis-trial","volume":"28","author":"Hoes","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0385","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1191\/0961203302lu189oa","article-title":"Clinical and immunogenetic characterization of Mexican patients with \u2018rhupus\u2019","volume":"11","author":"Sim\u00f3n","year":"2002","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2012.06.004_bb0390","doi-asserted-by":"crossref","first-page":"R144","DOI":"10.1186\/ar2036","article-title":"Presence of antibodies against cyclic citrullinated peptides in patients with \u2018rhupus\u2019: a cross-sectional study","volume":"8","author":"Amezcua-Guerra","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2012.06.004_bb0395","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10067-004-0951-2","article-title":"Lupus arthropathy: historical evolution from deforming arthritis to rhupus","volume":"23","author":"Fern\u00e1ndez","year":"2004","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0400","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1001\/archinte.1988.00380070117028","article-title":"\u2018Rhupus\u2019 syndrome","volume":"148","author":"Panush","year":"1988","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.autrev.2012.06.004_bb0405","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.autrev.2011.09.001","article-title":"Extra-articular manifestations of rheumatoid arthritis: an update","volume":"11","author":"Prete","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.06.004_bb0410","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s10067-005-1149-y","article-title":"Lupus arthropathy: a case series of patients with rhupus","volume":"25","author":"Fern\u00e1ndez","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0415","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.reuma.2010.12.006","article-title":"Rhupus: report of 4 cases","volume":"7","author":"Benavente","year":"2011","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.autrev.2012.06.004_bb0420","first-page":"540","article-title":"A retrospective clinical study of rhupus syndrome","volume":"45","author":"Mu","year":"2006","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"10.1016\/j.autrev.2012.06.004_bb0425","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3","article-title":"The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide","volume":"43","author":"Schellekens","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.06.004_bb0430","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1177\/0961203307087613","article-title":"Anti-citrullinated peptide antibodies in lupus patients with or without deforming arthropathy","volume":"17","author":"Dami\u00e1n-Abrego","year":"2008","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2012.06.004_bb0435","first-page":"77","article-title":"Associations of erosive arthritis with anti-cyclic citrullinated peptide antibodies and MHC Class II alleles in systemic lupus erythematosus","volume":"35","author":"Chan","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0440","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00011-008-8110-x","article-title":"Erosive arthritis in systemic lupus erythematosus is associated with high serum C-reactive protein and anti-cyclic citrullinated peptide antibodies","volume":"57","author":"Amezcua-Guerra","year":"2008","journal-title":"Inflamm Res"},{"key":"10.1016\/j.autrev.2012.06.004_bb0445","first-page":"50","article-title":"Diagnostic accuracy of currently available anti-double-stranded DNA antibody assays. An Italian multicentre study","volume":"29","author":"Ghirardello","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0450","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/ard.53.2.140","article-title":"Antiphospholipid antibodies (aPL) in systemic lupus erythematosus. Are they specific tools for the diagnosis of aPL syndrome?","volume":"53","author":"Ghirardello","year":"1994","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.06.004_bb0455","first-page":"S46","article-title":"The antiphospholipid antibody syndrome: diagnosis, skin manifestations and current therapy","volume":"24","author":"Asherson","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0460","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.autrev.2005.06.004","article-title":"Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the \u201cEuro-Lupus Project\u201d","volume":"5","author":"Cervera","year":"2006","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.06.004_bb0465","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1177\/0961203311400113","article-title":"Chronic polyarthritis as the first manifestation of juvenile systemic lupus erythematosus patients","volume":"20","author":"Cavalcante","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2012.06.004_bb0470","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1177\/0961203310388447","article-title":"Epidemiology and survival of systemic lupus erythematosus in Hong Kong Chinese","volume":"20","author":"Mok","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2012.06.004_bb0475","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ejim.2008.01.017","article-title":"Deforming arthropathy in systemic lupus erythematosus","volume":"19","author":"Pipili","year":"2008","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.autrev.2012.06.004_bb0480","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1191\/0961203304lu1067sr","article-title":"Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus","volume":"13","author":"Tam","year":"2004","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2012.06.004_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2011.12.010","article-title":"How to treat refractory arthritis in lupus?","author":"Artifoni","year":"2012","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.autrev.2012.06.004_bb0490","first-page":"708","article-title":"Successful treatment using cyclosporine in a patient with rhupus complicated by aplastic anemia: a case report and review of the literature","volume":"29","author":"Seo","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0495","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1177\/0961203311409273","article-title":"Rituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosus","volume":"20","author":"Pinto","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2012.06.004_bb0500","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/rheumatology\/kem021","article-title":"Systemic sclerosis-rheumatoid arthritis overlap syndrome: a unique combination of features suggests a distinct genetic, serological and clinical entity","volume":"46","author":"Sz\u00fccs","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2012.06.004_bb0505","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1093\/rheumatology\/keq205","article-title":"Usefulness of anti-cyclic citrullinated peptide antibody and rheumatoid factor to detect rheumatoid arthritis in patients with systemic sclerosis","volume":"49","author":"Ueda-Hayakawa","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2012.06.004_bb0510","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10067-007-0656-4","article-title":"A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis","volume":"27","author":"Santiago","year":"2008","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0515","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1136\/ard.2005.044602","article-title":"Radiological hand involvement in systemic sclerosis","volume":"65","author":"Avouac","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.06.004_bb0520","first-page":"91","article-title":"Clinical features of patients with systemic sclerosis accompanied by rheumatoid arthritis","volume":"21","author":"Jinnin","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0525","first-page":"1636","article-title":"Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease","volume":"34","author":"Lam","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0530","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1136\/ard.2008.096123","article-title":"An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis","volume":"68","author":"Denton","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.06.004_bb0535","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/01.rhu.0000191162.66288.27","article-title":"Infliximab-induced scleroderma in a patient with rheumatoid arthritis","volume":"11","author":"Ranganathan","year":"2005","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0540","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1007\/s10067-006-0229-y","article-title":"A case report of tumor necrosis factor-alpha antibody-induced thrombocytopenia associated with emerging IgM anticardiolipin antibody in patients with scleroderma overlap\/rheumatoid arthritis","volume":"26","author":"Hamaguchi","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0545","first-page":"2725","article-title":"Tumor necrosis factor-alpha antagonists induce lupus-like syndrome in patients with scleroderma overlap\/mixed connective tissue disease","volume":"30","author":"Christopher-Stine","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0550","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1136\/ard.2005.044453","article-title":"Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab","volume":"65","author":"Allanore","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.06.004_bb0555","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.autrev.2011.04.013","article-title":"Cells in systemic sclerosis: a possible target for therapy","volume":"10","author":"Bosello","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.06.004_bb0560","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000247238","article-title":"Systemic sclerosis (scleroderma) associated with discoid lupus erythematosus","volume":"187","author":"Sasaki","year":"1993","journal-title":"Dermatology"},{"key":"10.1016\/j.autrev.2012.06.004_bb0565","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/rheumatology\/34.10.908","article-title":"Detection of antiribosomal P protein antibodies in patients with systemic sclerosis","volume":"34","author":"Fujimoto","year":"1995","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0570","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1177\/096120339500400414","article-title":"Autoantibodies to topoisomerase I in a patient with systemic lupus erythematosus without features of scleroderma","author":"Stojanov","year":"1995","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2012.06.004_bb0575","first-page":"24","article-title":"A case report of typical scleroderma accompanied with serum abnormalities characteristic of SLE during the course","volume":"37","author":"Nishiyama","year":"1997","journal-title":"Ryumachi"},{"key":"10.1016\/j.autrev.2012.06.004_bb0580","first-page":"810","article-title":"A case of systemic lupus erythematosus overlapping with progressive systemic sclerosis accompanied by deposition of AA amyloid in the stomach","volume":"38","author":"Obata","year":"1998","journal-title":"Ryumachi"},{"key":"10.1016\/j.autrev.2012.06.004_bb0585","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1046\/j.1365-2133.2000.03492.x","article-title":"Development of systemic sclerosis in a patient with systemic lupus erythematosus and topoisomerase I antibody","volume":"142","author":"Katsumi","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0590","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s10067-002-0657-2","article-title":"Antitopoisomerase I antibody in patients with systemic lupus erythematosus\/sicca syndrome without a concomitant scleroderma: two case reports","volume":"22","author":"Al Attia","year":"2003","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0595","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s10067-004-1048-7","article-title":"Multiple avascular necrosis in a patient with systemic lupus erythematosus\/systemic sclerosis overlap syndrome","volume":"24","author":"Cavallasca","year":"2005","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0600","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00296-005-0084-1","article-title":"A case of overlap syndrome with rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis and secondary Sj\u00f6gren's syndrome","volume":"26","author":"Turkcapar","year":"2006","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2012.06.004_bb0605","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1346-8138.2006.00010.x","article-title":"Acquired ichthyosis associated with an overlap syndrome of systemic sclerosis and systemic lupus erythematosus","volume":"33","author":"Lee","year":"2006","journal-title":"J Dermatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0610","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3109\/s10165-006-0476-4","article-title":"A case of severe acute pancreatitis, in overlap syndrome of systemic sclerosis and systemic lupus erythematosus, successfully treated with plasmapheresis","volume":"16","author":"Suzuki","year":"2006","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0615","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00296-009-1232-9","article-title":"Necrotizing fasciitis in a patient with overlap syndrome of systemic sclerosis and systemic lupus erythematosus","volume":"31","author":"Chong","year":"2011","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2012.06.004_bb0620","doi-asserted-by":"crossref","first-page":"e676","DOI":"10.1111\/j.1365-2230.2009.03403.x","article-title":"Multifocal lesions of morphoea in a patient with systemic lupus erythematosus","volume":"34","author":"Ko","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0625","first-page":"5306","article-title":"Orchitis in lupus\/scleroderma overlap syndrome: a case report and literature review","volume":"17","author":"Boulis","year":"2010","journal-title":"Can J Urol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0630","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.reuma.2010.02.003","article-title":"Rapidly progressive fatal interstitial lung disease in a patient with an overlap syndrome of systemic lupus erythematosus and systemic sclerosis","volume":"7","author":"Sacnun","year":"2011","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.autrev.2012.06.004_bb0635","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/ard.50.5.323","article-title":"The progressive systemic sclerosis\/systemic lupus overlap: an unusual clinical progression","volume":"50","author":"Asherson","year":"1991","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.06.004_bb0640","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3143\/geriatrics.37.74","article-title":"A case of very late onset overlap syndrome of systemic sclerosis and systemic lupus erythematosus","volume":"37","author":"Takeda","year":"2000","journal-title":"Nihon Ronen Igakkai Zasshi"},{"key":"10.1016\/j.autrev.2012.06.004_bb0645","first-page":"103","article-title":"Thrombocytopenia responsive to warfarin in a patient with systemic sclerosis\u2013systemic lupus erythematosus overlap","volume":"13","author":"Kuwana","year":"1995","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0650","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1093\/ndt\/gfg347","article-title":"Reversible posterior leukoencephalopathy in a patient with systemic sclerosis\/systemic lupus erythematosus overlap syndrome","volume":"18","author":"Yong","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2012.06.004_bb0655","first-page":"337","article-title":"Secondary lethal catastrophic antiphospholipid syndrome in 24-years old female patient with overlap syndrome (systemic sclerosis and systemic lupus erythematosus)","volume":"20","author":"Cio\u0142kiewicz","year":"2006","journal-title":"Pol Merkur Lekarski"},{"key":"10.1016\/j.autrev.2012.06.004_bb0660","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1191\/096120301701548382","article-title":"Renal crisis in asclerodermic scleroderma\u2014lupus overlap syndrome","volume":"10","author":"Horn","year":"2001","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2012.06.004_bb0665","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.autrev.2010.06.005","article-title":"Anti-Scl-70 (topo-I) antibodies in SLE: myth or reality?","volume":"9","author":"Mahler","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.06.004_bb0670","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nrrheum.2009.238","article-title":"Autoantibodies as predictive tools in systemic sclerosis","volume":"6","author":"Nihtyanova","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0675","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1002\/art.21922","article-title":"Systemic sclerosis-associated Sj\u00f6gren's syndrome and relationship to the limited cutaneous subtype: results of a prospective study of sicca syndrome in 133 consecutive patients","volume":"54","author":"Avouac","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.06.004_bb0680","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3899\/jrheum.090866","article-title":"Similarities and differences between primary and secondary Sj\u00f6gren's syndrome","volume":"37","author":"Hern\u00e1ndez-Molina","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0685","doi-asserted-by":"crossref","first-page":"829751","DOI":"10.1155\/2011\/829751","article-title":"The role of intravenous immunoglobulin preparations in the treatment of systemic sclerosis","volume":"2011","author":"Baleva","year":"2011","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0690","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/acr.20495","article-title":"Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sj\u00f6gren's syndrome: a national multicentric retrospective study","volume":"63","author":"Rist","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2012.06.004_bb0695","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/ard.61.1.59","article-title":"Intravenous immunoglobulins control scleromyxedema","volume":"61","author":"Righi","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.06.004_bb0700","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1001\/jama.2010.1014","article-title":"Treatment of primary Sj\u00f6gren syndrome: a systematic review","volume":"304","author":"Ramos-Casals","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2012.06.004_bb0705","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1590\/S0104-42302011000300015","article-title":"Secondary Sj\u00f6gren's syndrome and disease activity of rheumatoid arthritis","volume":"57","author":"Antero","year":"2011","journal-title":"Rev Assoc Med Bras"},{"key":"10.1016\/j.autrev.2012.06.004_bb0710","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/PL00006853","article-title":"Extra-articular manifestations in 587 Italian patients with rheumatoid arthritis","volume":"19","author":"Cimmino","year":"2000","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2012.06.004_bb0715","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/ard.62.9.897","article-title":"Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity","volume":"62","author":"Carmona","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.06.004_bb0720","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/rheumatology\/keh455","article-title":"Prevalence of Sj\u00f6gren's syndrome in ambulatory patients according to the American-European Consensus Group criteria","volume":"44","author":"S\u00e1nchez-Guerrero","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2012.06.004_bb0725","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.rdc.2008.08.009","article-title":"Relationship of Sj\u00f6gren's syndrome to other connective tissue and autoimmune disorders","volume":"34","author":"Theander","year":"2008","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.autrev.2012.06.004_bb0730","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(05)66990-5","article-title":"Sj\u00f6gren's syndrome","volume":"366","author":"Fox","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2012.06.004_bb0735","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1136\/ard.2003.019794","article-title":"Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sj\u00f6gren's syndrome","volume":"64","author":"Gottenberg","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.06.004_bb0740","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s10067-005-1104-y","article-title":"Anti-CCP and antikeratin antibodies in rheumatoid arthritis, primary Sj\u00f6gren's syndrome, and Wegener's granulomatosis","volume":"24","author":"Kamali","year":"2005","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0745","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3899\/jrheum.080193","article-title":"Determination of the subset of Sjogren's syndrome with articular manifestations by anticyclic citrullinated peptide antibodies","volume":"36","author":"Iwamoto","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0750","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1136\/ard.58.7.415","article-title":"Sicca symptoms, saliva and tear production, and disease variables in 636 patients with rheumatoid arthritis","volume":"58","author":"Uhlig","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.06.004_bb0755","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1600-0714.2010.00899.x","article-title":"Sicca symptoms, and lacrimal and salivary flow in Albanian patients with rheumatoid arthritis","volume":"39","author":"Aliko","year":"2010","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.autrev.2012.06.004_bb0760","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.autrev.2010.11.009","article-title":"The kaleidoscope of glucocorticoid effects on immune system","volume":"10","author":"Zen","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.06.004_bb0765","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.autrev.2007.03.009","article-title":"Potential target of infliximab in autoimmune and inflammatory diseases","volume":"6","author":"Atzeni","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.06.004_bb0770","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s10067-008-0885-1","article-title":"A case of autoimmune hepatitis exacerbated by the administration of etanercept in the patient with rheumatoid arthritis","volume":"27","author":"Harada","year":"2008","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0775","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2169\/internalmedicine.50.4879","article-title":"Improvement of rheumatoid arthritis and autoimmune hepatitis in a patient treated with the tumor necrosis factor inhibitor, etanercept","volume":"50","author":"Umekita","year":"2011","journal-title":"Intern Med"},{"key":"10.1016\/j.autrev.2012.06.004_bb0780","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1365-2796.2009.02207.x","article-title":"CD20-depleting therapy in autoimmune diseases: from basic research to the clinic","volume":"267","author":"Perosa","year":"2010","journal-title":"J Intern Med"},{"key":"10.1016\/j.autrev.2012.06.004_bb0785","first-page":"717","article-title":"Subclinical myositis is common in primary Sj\u00f6gren's syndrome and is not related to muscle pain","volume":"29","author":"Lindvall","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0790","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.autrev.2010.05.004","article-title":"Immunological profile in primary Sj\u00f6gren syndrome: clinical significance, prognosis and long-term evolution to other auto-immune disease","volume":"9","author":"Fauchais","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.06.004_bb0795","first-page":"37","article-title":"A case of Sj\u00f6gren's syndrome with dermatomyositis who died of rapidly progressive interstitial pneumonia","volume":"41","author":"Fukumura","year":"2001","journal-title":"Ryumachi"},{"key":"10.1016\/j.autrev.2012.06.004_bb0800","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2177\/jsci.23.141","article-title":"A case of Sj\u00f6gren's syndrome complicated by polymyositis and sarcoidosis with HLA-B7 and DR8: common causes of susceptibility for these diseases","volume":"23","author":"Koarada","year":"2000","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"key":"10.1016\/j.autrev.2012.06.004_bb0805","first-page":"178","article-title":"Dermatomyositis associated with Sj\u00f6gren's syndrome: VEGF involvement in vasculitis","volume":"23","author":"Ohno","year":"2004","journal-title":"Clin Neuropathol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0810","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.neurol.2009.02.011","article-title":"Polymyositis revealing a Sjogren's syndrome","volume":"166","author":"Giroux","year":"2010","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.autrev.2012.06.004_bb0815","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1067\/mjd.2002.121037","article-title":"Prevalence of 52-kd and 60-kd Ro\/SS-A autoantibodies in Japanese patients with polymyositis\/dermatomyositis","volume":"47","author":"Kubo","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0820","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/08916930600622645","article-title":"Clinical implications of autoantibody screening in patients with autoimmune myositis","volume":"39","author":"Ghirardello","year":"2006","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2012.06.004_bb0825","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.autrev.2011.06.007","article-title":"Therapy of polymyositis and dermatomyositis","volume":"11","author":"Marie","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.06.004_bb0830","first-page":"6","article-title":"Effects of rituximab therapy on quality of life in patients with primary Sj\u00f6gren's syndrome","volume":"29","author":"Devauchelle-Pensec","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0835","first-page":"363","article-title":"Rituximab is effective in the treatment of patients with idiopathic inflammatory myopathy","volume":"29","author":"Garcia-Hernandez","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2012.06.004_bb0840","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.autrev.2011.10.022","article-title":"Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases?","volume":"11","author":"Costenbader","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.06.004_bb0845","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.autrev.2011.11.017","article-title":"Genes, tolerance and systemic autoimmunity","volume":"11","author":"Singh","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.06.004_bb0850","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.autrev.2011.10.003","article-title":"The genomics of autoimmune disease in the era of genome-wide association studies and beyond","volume":"11","author":"Lessard","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.06.004_bb0855","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.autrev.2011.10.002","article-title":"HLA and Sj\u00f6gren's syndrome susceptibility. A meta-analysis of worldwide studies","volume":"11","author":"Cruz-Tapias","year":"2012","journal-title":"Autoimmun Rev"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997212001218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997212001218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,30]],"date-time":"2019-06-30T04:41:01Z","timestamp":1561869661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997212001218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":171,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S1568997212001218"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2012.06.004","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}